Tech Company Financing Transactions
Seattle Genetics Funding Round
Takeda Ventures participated in a $9 million funding round for Seattle Genetics. The round was announced on 1/21/2014.
Transaction Overview
Company Name
Announced On
1/21/2014
Transaction Type
Venture Equity
Amount
$9,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Seattle Genetics and Takeda are jointly developing Adcetris, which has been approved in 39 countries.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
21717 - 30th Drive S.E. Building 3
Bothell, WA 98021
USA
Bothell, WA 98021
USA
Phone
Website
Email Address
Overview
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Clay Siegall
Chief Financial Officer
Todd Simpson
Chief Medical Officer
Roger Dansey
Chief Technical Officer
Vaughn Himes
Executive Vice President
Darren Cline
Vice President
Rachel Lenington
VP - Bus. Development
Natasha Hernday
VP - General Counsel
Jean Liu
VP - Human Resources
Christopher Pawlowicz
Browse more venture capital transactions:
Prev: 1/21/2014: Ceres Imaging venture capital transaction
Next: 1/21/2014: Kareo venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs